Detalhe da pesquisa
1.
Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes.
Oncologist
; 2024 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38417095
2.
Improving biomarker testing in advanced non-small-cell lung cancer and metastatic colorectal cancer: experience from a large community oncology network in the USA.
Future Oncol
; 19(20): 1397-1414, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37318757
3.
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021).
Lancet Oncol
; 23(7): 899-909, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35690072
4.
Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia.
Future Oncol
; 17(35): 4959-4969, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34783255
5.
Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences.
Target Oncol
; 18(5): 727-734, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37728835
6.
A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer.
Clin Cancer Res
; 29(17): 3292-3300, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37339186
7.
Prognostic Impact of Missed Chemotherapy Doses During Chemoradiation Therapy for Non-Small Cell Lung Cancer.
Am J Clin Oncol
; 41(4): 362-366, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27322697